Katie S Murray1, Ashley G Winter2, Renato Beluco Corradi3, Stephen LaRosa3, Sylvia Jebiwott3, Alexander Somma3, Haruyuki Takaki4, Govindarajan Srimathveeravalli4, Michelle Lepherd5, Sebastien Monette5, Kwanghee Kim3, Avigdor Scherz6, Jonathan A Coleman7. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, New York Presbyterian Hospital, New York, New York; Weill-Cornell Medical College, New York Presbyterian Hospital, New York, New York; New York Presbyterian Hospital, New York, New York; Rockefeller University, New York, New York. 3. Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. 7. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, New York Presbyterian Hospital, New York, New York. Electronic address: colemanj@mskcc.org.
Abstract
PURPOSE: Surgical management of upper tract urothelial carcinoma requires kidney and ureter removal, compromising renal function. Nonsurgical alternatives have potentially prohibitive safety concerns. We examined the feasibility and safety of ablation of the ureter and renal pelvis using endoluminal vascular targeted photodynamic therapy in a porcine model. We also report the efficacy of WST11 vascular targeted photodynamic therapy in a murine model. MATERIALS AND METHODS: After receiving approval we performed a total of 28 endoluminal ablations in the ureters and renal pelvis of 18 swine. Intravenous infusion of WST11 (4 mg/kg) followed by 10-minute laser illumination was done via percutaneous access or a retrograde ureteroscopic approach. Animals were followed clinically with laboratory testing, imaging and histology, which were evaluated at several postablation time points. A murine xenograft was created with the 5637 human urothelial cell carcinoma line to determine sensitivity to this therapy. RESULTS: At 24 hours 50 mW/cm laser fluence produced superficial necrosis of the ureter. Deeper necrosis penetrating the muscularis propria or adventitia was produced by treatment with 200 mW/cm in the ureter and the renal pelvis. At 4 weeks superficial urothelium had regenerated over the treatment site. No symptomatic obstruction, clinically relevant hydronephrosis or abnormality of laboratory testing was noted up to 4 weeks. Of the mice 80% had no evidence of tumor 19 days after WST11 vascular targeted photodynamic therapy. CONCLUSIONS: Urothelial cell carcinoma appears to be sensitive to WST11 vascular targeted photodynamic therapy. The depth of WST11 vascular targeted photodynamic therapy treatment effects can be modulated in a dose dependent manner by titrating light intensity. Moreover, when applied to the porcine upper urinary tract, this treatment modality is feasible via antegrade and retrograde access.
PURPOSE: Surgical management of upper tract urothelial carcinoma requires kidney and ureter removal, compromising renal function. Nonsurgical alternatives have potentially prohibitive safety concerns. We examined the feasibility and safety of ablation of the ureter and renal pelvis using endoluminal vascular targeted photodynamic therapy in a porcine model. We also report the efficacy of WST11 vascular targeted photodynamic therapy in a murine model. MATERIALS AND METHODS: After receiving approval we performed a total of 28 endoluminal ablations in the ureters and renal pelvis of 18 swine. Intravenous infusion of WST11 (4 mg/kg) followed by 10-minute laser illumination was done via percutaneous access or a retrograde ureteroscopic approach. Animals were followed clinically with laboratory testing, imaging and histology, which were evaluated at several postablation time points. A murine xenograft was created with the 5637 humanurothelial cell carcinoma line to determine sensitivity to this therapy. RESULTS: At 24 hours 50 mW/cm laser fluence produced superficial necrosis of the ureter. Deeper necrosis penetrating the muscularis propria or adventitia was produced by treatment with 200 mW/cm in the ureter and the renal pelvis. At 4 weeks superficial urothelium had regenerated over the treatment site. No symptomatic obstruction, clinically relevant hydronephrosis or abnormality of laboratory testing was noted up to 4 weeks. Of the mice 80% had no evidence of tumor 19 days after WST11 vascular targeted photodynamic therapy. CONCLUSIONS:Urothelial cell carcinoma appears to be sensitive to WST11 vascular targeted photodynamic therapy. The depth of WST11 vascular targeted photodynamic therapy treatment effects can be modulated in a dose dependent manner by titrating light intensity. Moreover, when applied to the porcine upper urinary tract, this treatment modality is feasible via antegrade and retrograde access.
Authors: Abdel-Rahmène Azzouzi; Eric Barret; Caroline M Moore; Arnaud Villers; Clare Allen; Avigdor Scherz; Gordon Muir; Michel de Wildt; Neil J Barber; Souhil Lebdai; Mark Emberton Journal: BJU Int Date: 2013-10 Impact factor: 5.588
Authors: Simon Y Kimm; Tatum V Tarin; Sébastien Monette; Govindarajan Srimathveeravalli; Daniel Gerber; Jeremy C Durack; Stephen B Solomon; Peter T Scardino; Avigdor Scherz; Jonathan Coleman Journal: Radiology Date: 2016-03-17 Impact factor: 11.105
Authors: Angeles Juarranz; Pedro Jaén; Francisco Sanz-Rodríguez; Jesús Cuevas; Salvador González Journal: Clin Transl Oncol Date: 2008-03 Impact factor: 3.405
Authors: Kwanghee Kim; Hanwen Zhang; Stephen La Rosa; Sylvia Jebiwott; Pooja Desai; Simon Kimm; Avigdor Scherz; Joseph A O'Donoghue; Wolfgang A Weber; Jonathan A Coleman Journal: Clin Cancer Res Date: 2017-01-20 Impact factor: 12.531
Authors: Lucas Nogueira; Andrew T Tracey; Ricardo Alvim; Peter Reisz; Avigdor Scherz; Jonathan A Coleman; Kwanghee Kim Journal: Molecules Date: 2020-11-19 Impact factor: 4.411
Authors: Barak Rosenzweig; Renato B Corradi; Sadna Budhu; Ricardo Alvim; Pedro Recabal; Stephen La Rosa; Alex Somma; Sebastien Monette; Avigdor Scherz; Kwanghee Kim; Jonathan A Coleman Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379
Authors: Ricardo G Alvim; Petrina Georgala; Lucas Nogueira; Alexander J Somma; Karan Nagar; Jasmine Thomas; Laura Alvim; Amelia Riegel; Christopher Hughes; Jie Chen; Augusto B Reis; Souhil Lebdai; Avigdor Scherz; Steven Zanganeh; Rui Gardner; Kwanghee Kim; Jonathan A Coleman Journal: Molecules Date: 2021-06-19 Impact factor: 4.411